Loss of profitability and impairment of pharmaceutical marketing rights, etc.
First written in FY2017-Q3. 3 of 4 entries say "Materialised", first in FY2017-Q3. Latest entry: FY2025.
Nippon Shinyaku moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「As a result of the impairment test, the company recognized impairment losses of ¥722 million for the previous consolidated accounting year and ¥849 million for the current consolidated accounting year on marketing rights in the pharmaceutical segment.」
The impairment loss on pharmaceutical marketing rights increased from ¥722 million to ¥849 million, expanding the scale of the risk associated with declining profitability. - FY2024MaterialisedAnnual report
「As a result of the impairment test, the company recognized an impairment loss of ¥722 million on marketing rights in the pharmaceutical segment for the consolidated accounting year.」
The risk of declining profitability for pharmaceutical marketing rights and other assets also materialized during the year, and the company recorded an impairment loss of ¥722 million. - FY2023MaterialisedAnnual report
「For marketing rights and other assets deemed unlikely to generate future profitability, the recoverable amount was assessed as zero, and the unamortized balance was recognized as an impairment loss and recorded as an extraordinary loss.」
The company also recorded an impairment loss of ¥616 million on pharmaceutical marketing rights and other assets in fiscal 2023. - FY2017-Q3MaterialisedAnnual report
「For marketing rights and other assets deemed unlikely to generate future profitability, the recoverable amount was assessed as zero, and the unamortized balance was recognized as an impairment loss and recorded as an extraordinary loss.」
The company determined that pharmaceutical marketing rights and other assets had no future profitability and recorded the unamortized balance of ¥766 million as an impairment loss.